Results 131 to 140 of about 5,967 (167)
NTRK fusion-positive cancers and TRK inhibitor therapy [PDF]
Nature Reviews Clinical Oncology, 2018 NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the clinic using a variety of methods, including tumour DNA and RNA sequencing and plasma cell-free DNA profiling.
Alexander Drilon +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The promise of TRK inhibitors in pediatric cancers with NTRK fusions
Cancer Genetics, 2022NTRK fusions are rare oncogenic drivers that occur across a range of pediatric cancers. These include infantile fibrosarcoma and secretory breast cancer in which such fusions are nearly pathognomonic, and a spectrum of more common pediatric cancers in which NTRK fusions occur at a lower frequency.
Emily R, Blauel, Theodore W, Laetsch
openaire +2 more sources
NTRK-Fusions – A new kid on the block
Pathology - Research and Practice, 2019The neurotrophic tyrosine receptor kinases (NTRK) play an important role in the development and function of the nervous system. Fusions involving NTRK and a wide range of genes that act as fusion partners are oncogenic and activate well-known signal transduction pathways like the MAPK-ERK pathway.
Märkl, Bruno +2 more
openaire +2 more sources
NTRK fusions in lung cancer: From biology to therapy
Lung Cancer, 2021Fusions involving TRK protein tyrosine kinases are oncogenic drivers in a variety of tumors in children and adults, with a prevalence of ∼0.2% in non-small cell lung cancer. Diagnosis can be challenging due to structural features such as NTRK intron length, but next-generation sequencing (NGS), including RNA-based NGS, increases detection.
Guilherme Harada +3 more
openaire +2 more sources
NTRK fusions in thyroid cancer: Pathology and clinical aspects
Critical Reviews in Oncology/Hematology, 2023Thyroid cancer is the most common endocrine cancer. Neurotrophic tyrosine receptor kinase (NTRK) fusions are oncogenic drivers in multiple solid tumors, including thyroid cancer. NTRK fusion thyroid cancer has unique pathological features such as mixed structure, multiple nodes, lymph node metastasis, and a background of chronic lymphocytic thyroiditis.
Yanhui Ma +8 more
openaire +2 more sources
The oncogenic roles of NTRK fusions and methods of molecular diagnosis
Cancer Genetics, 2021The NTRK gene family is composed of NTRK1, NTRK2, and NTRK3, which encode three tropomyosin-receptor kinases, belonging to a class of tyrosine kinase receptors. These proteins are known to play roles in cell proliferation, differentiation, apoptosis, and survival. Fusions involving the NTRK genes are long known as drivers in many tumors.
Erfan, Aref-Eshghi +3 more
openaire +2 more sources
[NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].
Gan to kagaku ryoho. Cancer & chemotherapy, 2022Neurotrophic tyrosine receptor kinase(NTRK)gene variants have been reported in a variety of cancer types. The prevalence of NTRK gene variants is less than 1% in many types of solid cancer. The highest NTRK gene fusions frequencies were found in secretary breast carcinoma and infantile fibrosarcoma.
Misao, Fukuda, Yoichi, Naito
openaire +1 more source
Novel fusion sarcomas including targetable NTRK and ALK
Annals of Diagnostic Pathology, 2021Challenging emerging entities with distinctive molecular signatures may benefit from algorithms for diagnostic work-up.Fusion sarcomas (2020-2021, during pandemic) were diagnosed by clinicoradiology, morphology, phenotype, and next-generation sequencing (NGS).Six fusion sarcomas in two males and four females involved the chest-wall, neck, or ...
Tiane, Chen +9 more
openaire +2 more sources